Chest
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Section snippets
Overview of the Approach to the Patient With PAH
The treatment of PAH begins with a thorough evaluation seeking underlying causes and contributing factors. The diagnosis of PAH is thoroughly discussed in Chapter 2. Initial therapy may be directed at the underlying cause or contributing factor, with examples including supplemental oxygen for hypoxemia, continuous positive airway pressure therapy and supplemental oxygen for obstructive sleep apnea, anticoagulation, and consideration of pulmonary thromboendarterectomy for PAH due to
Vasodilator Testing
Patients with IPAH who respond to vasodilators acutely have an improved survival with the long-term use of a CCB. As such, testing of vasoreactivity is an important part of the evaluation of any patient with PAH. Over the years, investigators have used a number of agents to acutely test vasodilator responsiveness, and have used various definitions of a response including reductions in either pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR), or both. These different
Introduction/Rationale
Prostacyclin is a metabolite of arachidonic acid produced primarily in vascular endothelium. It is a potent vasodilator, affecting both the pulmonary and systemic circulations. It also has antiplatelet aggregatory effects, and the pathology of the disease may include microscopic in situ thromboses. There is evidence to suggest that a relative deficiency of prostacyclin may contribute to the pathogenesis of PAH. In a landmark study, Christman et al9 reported a deficiency of prostacyclin and
Introduction/Rationale
Endothelin-receptor antagonism is a promising therapeutic approach supported by increasing evidence of the pathogenic role of endothelin-1 in PAH.38 Endothelin-1 is a potent vasoconstrictor and a smooth-muscle mitogen that might contribute to the increase in vascular tone and the pulmonary vascular hypertrophy associated with PAH.39 In addition, endothelin-1 expression, production, and concentration in plasma4041 and lung tissue42 are elevated in patients with PAH, and these levels are
Rationale
Mechanisms that modulate cyclic guanosine 3′-5′ monophosphate (cGMP) content in vascular smooth muscle play critical roles in the regulation of vascular tone, growth, and structure. The vasodilator effects of NO are dependent on its ability to augment and sustain cGMP content in vascular smooth muscle. Once produced, NO directly activates soluble guanylate cyclase, which increases cGMP production. cGMP then activates cGMP kinase, opens potassium channels, and causes vasorelaxation. The effects
Rationale
NO contributes to the maintenance of normal vascular function and structure. Recognition of the importance of NO as an endogenous vasodilator77 was followed by experimental and clinical observations indicating its physiologic roles in the maintenance of normal basal vascular resistance.777879 That deficient function of the NO signaling system may be an important contributor to the pathogenesis of diverse cardiovascular disorders has come from abundant observations of impaired
Combination Therapy
With the development of therapeutic agents with different mechanisms of action, considerable interest has developed in the possibility of combination therapy, similar to the strategies utilized in the treatment of systemic hypertension and many forms of cancer. Some agents, such as phosphodiesterase inhibitors, might enhance and prolong the effects of others, like the prostanoids. Other combinations might simply approach the problem of PAH from different mechanistic angles, and therefore have
Children
In decades past, the early presentation of severe PAH during infancy or early childhood was typically associated with a rapidly progressive disease and fatal outcome. The National Institutes of Health PPH Registry in the 1980s initially suggested a worse survival in children < 16 years of age, with a mean survival of 10 months in contrast to adults, in whom the mean survival was 2.8 years after diagnosis.135 However, this study135 included only small numbers of pediatric cases, and preceded the
Summary
The treatment of PAH is advancing rapidly. Multicenter RCTs have provided a basis for evidence-based practice. The treatment algorithm (Fig 1) attempts to summarize the current approach to therapy for PAH. Recommendations regarding therapy obviously need to be applied in light of the individual patient's specific situation. The importance of a thorough diagnostic evaluation, looking for underlying causes and contributing factors, cannot be overemphasized. Educational efforts have contributed to
Summary of Recommendations
- 1.
Patients with IPAH should undergo acute vasoreactivity testing using a short-acting agent such as IV epoprostenol, adenosine, or inhaled NO. Level of evidence: fair; benefit: substantial; grade of recommendation: A.
- 2.
Patients with PAH associated with underlying processes, such as scleroderma or congenital heart disease, should undergo acute vasoreactivity testing. Level of evidence: expert opinion; benefit: small/weak; grade of recommendation: E/C.
- 3.
Patients with PAH should undergo vasoreactivity
References (192)
- et al.
Comparison of the effects of adenosine and nifedipine in pulmonary hypertension
J Am Coll Cardiol
(1992) - et al.
The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
J Am Coll Cardiol
(1999) - et al.
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion
J Am Coll Cardiol
(1997) - et al.
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
J Am Coll Cardiol
(2002) - et al.
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
Lancet
(1991) - et al.
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group
J Am Coll Cardiol
(2000) - et al.
Orally active prostacyclin analogue in primary pulmonary hypertension
Lancet
(1997) - et al.
Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium
Gen Pharmacol
(1996) - et al.
Short-term hemodynamic effect of a new oral PGI2analogue, beraprost, in primary and secondary pulmonary hypertension
Am J Cardiol
(1996) - et al.
Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
J Am Coll Cardiol
(1999)
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
J Am Coll Cardiol
Beraprost therapy for pulmonary arterial hypertension
J Am Coll Cardiol
Endothelin-1: a mediator of pulmonary hypertension?
Pulm Pharmacol Ther
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension
Chest
Endothelin antagonists
Lancet
Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function
Ann Thorac Surg
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
Lancet
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study
Chest
Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
Trends Pharmacol Sci
The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance
Pulm Pharmacol
Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease
J Thorac Cardiovasc Surg
Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension
Am J Cardiol
Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension
Chest
Nitric oxide: its identity and role in blood pressure control
Life Sci
Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide
Int J Cardiol
Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine
Lancet
Atherosclerosis: risk factors and the vascular endothelium
Am Heart J
Lack of contribution of nitric oxide to basal vasomotor tone in heart failure
Am J Cardiol
Endothelial function in congestive heart failure
Am Heart J
The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease
Prog Cardiovasc Dis
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
N Engl J Med
Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin
Am J Respir Crit Care Med
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
Eur Respir J
Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation
Eur Heart J
Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension
Jpn Circ J
Primary pulmonary hypertension: natural history and the importance of thrombosis
Circulation
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
N Engl J Med
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
Am J Respir Crit Care Med
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group
N Engl J Med
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial
Ann Intern Med
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
Ann Intern Med
Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
N Engl J Med
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy
Circulation
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension
J Cardiovasc Pharmacol
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
Am J Respir Crit Care Med
Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man
Eur J Clin Pharmacol
Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
Eur Respir J
Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group
Ann Intern Med
Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
N Engl J Med
Cited by (431)
Contemporary Pharmacotherapeutic Approach in Pulmonary Arterial Hypertension
2021, Clinics in Chest MedicinePulmonary hypertension and pregnancy outcomes: Systematic Review and Meta-analysis
2020, European Journal of Obstetrics and Gynecology and Reproductive BiologyCitrulline in health and disease. Review on human studies
2018, Clinical NutritionCitation Excerpt :The cytosolic portion of the urea cycle was thought to be enabling localized, intracellular production of L-ARG from CIT within the pulmonary endothelium as well as in hepatocytes. Curiously these papers, which report on work from more than a decade ago, do not seem to have been followed-up by their authors or others in the field [38,39]. Electrophysiological mechanisms may also be important.
Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension
2018, Journal of Psychosomatic Research
For financial disclosure information see page 1S.